Monoclonal Antibodies: New Research
This new and important international source of information beings together leading-edge research dedicated to monoclonal antibodies. Monoclonal antibodies (MAbs) are: antibodies of exceptional purity and specificity; components of the immune system; able to recognise and bind to a specific antigen. Monoclonal antibodies are currently utilised in many diagnostic procedures, including: measuring protein and drug levels in serum; typing tissue and blood; identifying infectious agents; identifying clusters of differentiation for the classification and follow-up therapy of leukaemias and lymphomas; identifying tumour antigens and auto-antibodies; identifying the specific cells involved in the immune response; identifying and quantifying hormones. For example, monoclonal antibodies (MABs or MOABs) work on cancer cells in the same way natural antibodies work, by identifying and binding to the target cells. They then alert other cells in the immune system to the presence of the cancer cells. MABs are specific for a particular antigen-one designed for a B-cell lymphoma will not work on cells for ovarian cancer cells for example.
What people are saying - Write a review
We haven't found any reviews in the usual places.
A Monoclonal Antibody against αEnolase Plasminogen Receptor with Inhibitory Properties A Useful Tool to Study Pericellular Plasminogen Activati...
Quantitative Analysis of AntibodyAntigen Interactions using Immobilized Ligands Kinetic Exclusion Assays are More Accurate than Surface Plasmo...
Trastuzumab The Experience of the Hellenic Cooperative Oncology Group HeCOG
abciximab adjuvant angioplasty angioplasty and stenting anti-fluorescein antibody antigens bacterial BIAcore binding reaction binding sites Biochem Biol biosensor bolus breast cancer C2C12 cells capsular polysaccharides cardiac carotid cell surface chemotherapy clinical conjugate coronary stenting differentiation disease progression DMSO dose epitope Finne fluorescein fluorescein-BSA gemcitabine glycoprotein IIb/IIIa inhibitors Glycoprotein IIb/IIIa Receptor GP IIb/IIIa grade Häyrinen heparin HER2 hybridoma immune immunogens Immunol Infect infusion inhibition interactions Jennings HJ kinetic exclusion assays KinExA LVEF mAb production median MenB meningitis meningococcal metastatic breast cancer mg/kg mice molecule monoclonal antibody muscle regeneration myoblast myocardial infarction myogenesis Neisseria meningitidis neutropenia o-enolase plasminogen receptor overexpressing p38 MAPK paclitaxel patients phase placebo plasmin plasmin activity plasminogen activation platelet Platelet Glycoprotein IIb/IIIa polysaccharide polysialic acid primary end protein rate constant response rate restenosis role serum stopped flow surface plasmon resonance therapy tissue toxicity trastuzumab treatment trial tumor vaccine vitro weekly paclitaxel
Page 162 - Atreya, R., Mudter, J., Finotto, S., Mullberg, J., Jostock, T., Wirtz, S., Schutz, M., Bartsch, B., Holtmann, M., Becker, C., Strand, D., Czaja, J., Schlaak, J. F., Lehr, HA, Autschbach, F., Schurmann, G., Nishimoto, N., Yoshizaki, K., Ito, H., Kishimoto, T., Galle, PR, Rose-John, S., and Neurath, MF (2000).